Video

Educated Patient Multiple Myeloma Summit On-Demand: Nov. 21, 2020

Author(s):

CURE Media Group

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

Related Videos
Image of woman with blonde hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Related Content
Illustration of cells.
March 10th 2025

Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma

Spencer Feldman
Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of bladder.
February 21st 2025

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

Roman Fabbricatore
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of bladder cancer.
February 20th 2025

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Jax DiEugenio
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
Maintenance Bavencio with Inlyta treatment interruption is feasible in patients with mRCC: © SciePro - stock.adobe.com.
February 19th 2025

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

Jax DiEugenio
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.